Economic Incentives and vDOT for Latent Tuberculosis Infection

Description

The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.

Conditions

Latent Tuberculosis

Study Overview

Study Details

Study overview

The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.

Economic Incentives and Video Directly Observed Therapy to Promote Adherence to Latent Tuberculosis Infection

Economic Incentives and vDOT for Latent Tuberculosis Infection

Condition
Latent Tuberculosis
Intervention / Treatment

-

Contacts and Locations

Baltimore

Baltimore City Health Department, and Baltimore metropolitan area clinics and health departments, Baltimore, Maryland, United States, 21205

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years old or older,
  • * diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians
  • * reside in Baltimore metro area
  • * speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board
  • * prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin
  • * younger than 18 years old
  • * diagnosed with active TB
  • * prescribed an alternative treatment regimen for latent TB
  • * pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated)
  • * participant's spoken language does not have a translated long or short consent form

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Johns Hopkins University,

Maunank Shah, MD, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

2026-10-15